Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Celgene Corporation
Information provided by (Responsible Party):
Pierluigi Porcu, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01129180
First received: May 17, 2010
Last updated: February 18, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)